MiMedx Group Statistics
Total Valuation
MiMedx Group has a market cap or net worth of $620.21 million. The enterprise value is $501.58 million.
| Market Cap | 620.21M |
| Enterprise Value | 501.58M |
Important Dates
The last earnings date was Wednesday, July 29, 2026, after market close.
| Earnings Date | Jul 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MiMedx Group has 145.76 million shares outstanding. The number of shares has decreased by -0.13% in one year.
| Current Share Class | 145.76M |
| Shares Outstanding | 145.76M |
| Shares Change (YoY) | -0.13% |
| Shares Change (QoQ) | -0.44% |
| Owned by Insiders (%) | 1.91% |
| Owned by Institutions (%) | 56.17% |
| Float | 110.91M |
Valuation Ratios
The trailing PE ratio is 100.17 and the forward PE ratio is 422.00.
| PE Ratio | 100.17 |
| Forward PE | 422.00 |
| PS Ratio | 1.78 |
| Forward PS | 2.20 |
| PB Ratio | 2.93 |
| P/TBV Ratio | 3.43 |
| P/FCF Ratio | 14.21 |
| P/OCF Ratio | 13.71 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.18, with an EV/FCF ratio of 11.55.
| EV / Earnings | 82.38 |
| EV / Sales | 1.45 |
| EV / EBITDA | 25.18 |
| EV / EBIT | 58.73 |
| EV / FCF | 11.55 |
Financial Position
The company has a current ratio of 5.33, with a Debt / Equity ratio of 0.08.
| Current Ratio | 5.33 |
| Quick Ratio | 4.60 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.84 |
| Debt / FCF | 0.39 |
| Interest Coverage | 5.41 |
Financial Efficiency
Return on equity (ROE) is 2.88% and return on invested capital (ROIC) is 4.78%.
| Return on Equity (ROE) | 2.88% |
| Return on Assets (ROA) | 1.91% |
| Return on Invested Capital (ROIC) | 4.78% |
| Return on Capital Employed (ROCE) | 3.61% |
| Weighted Average Cost of Capital (WACC) | 11.84% |
| Revenue Per Employee | $439,571 |
| Profits Per Employee | $7,722 |
| Employee Count | 808 |
| Asset Turnover | 1.24 |
| Inventory Turnover | 3.28 |
Taxes
In the past 12 months, MiMedx Group has paid $5.30 million in taxes.
| Income Tax | 5.30M |
| Effective Tax Rate | 45.91% |
Stock Price Statistics
The stock price has decreased by -39.60% in the last 52 weeks. The beta is 1.41, so MiMedx Group's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -39.60% |
| 50-Day Moving Average | 3.99 |
| 200-Day Moving Average | 4.99 |
| Relative Strength Index (RSI) | 53.37 |
| Average Volume (20 Days) | 1,485,682 |
Short Selling Information
The latest short interest is 7.52 million, so 5.16% of the outstanding shares have been sold short.
| Short Interest | 7.52M |
| Short Previous Month | 7.53M |
| Short % of Shares Out | 5.16% |
| Short % of Float | 6.78% |
| Short Ratio (days to cover) | 5.65 |
Income Statement
In the last 12 months, MiMedx Group had revenue of $355.17 million and earned $6.24 million in profits. Earnings per share was $0.04.
| Revenue | 355.17M |
| Gross Profit | 280.05M |
| Operating Income | 8.75M |
| Pretax Income | 11.53M |
| Net Income | 6.24M |
| EBITDA | 20.41M |
| EBIT | 8.75M |
| Earnings Per Share (EPS) | $0.04 |
Balance Sheet
The company has $135.84 million in cash and $17.21 million in debt, with a net cash position of $118.63 million or $0.81 per share.
| Cash & Cash Equivalents | 135.84M |
| Total Debt | 17.21M |
| Net Cash | 118.63M |
| Net Cash Per Share | $0.81 |
| Equity (Book Value) | 216.00M |
| Book Value Per Share | 1.48 |
| Working Capital | 166.87M |
Cash Flow
In the last 12 months, operating cash flow was $46.15 million and capital expenditures -$1.65 million, giving a free cash flow of $44.50 million.
| Operating Cash Flow | 46.15M |
| Capital Expenditures | -1.65M |
| Depreciation & Amortization | 11.66M |
| Net Borrowing | -1.25M |
| Free Cash Flow | 44.50M |
| FCF Per Share | $0.31 |
Margins
Gross margin is 78.85%, with operating and profit margins of 2.46% and 1.76%.
| Gross Margin | 78.85% |
| Operating Margin | 2.46% |
| Pretax Margin | 3.25% |
| Profit Margin | 1.76% |
| EBITDA Margin | 5.75% |
| EBIT Margin | 2.46% |
| FCF Margin | 12.53% |
Dividends & Yields
MiMedx Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.13% |
| Shareholder Yield | 0.13% |
| Earnings Yield | 0.99% |
| FCF Yield | 7.04% |
Analyst Forecast
The average price target for MiMedx Group is $6.60, which is 55.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.60 |
| Price Target Difference | 55.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -6.55% |
| EPS Growth Forecast (3Y) | -16.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MiMedx Group has an Altman Z-Score of 9.51 and a Piotroski F-Score of 6.
| Altman Z-Score | 9.51 |
| Piotroski F-Score | 6 |